Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options.

In patients with liver disease, thrombocytopenia is a clinical feature that may represent an obstacle to invasive diagnostic or therapeutic procedures, chemotherapy, and anti-viral treatment. Stimulation of the bone marrow is the most promising therapeutic intervention for thrombocytopenia in patients with chronic liver disease. The description of thrombopoietin and its (de)regulation in patients with chronic liver disease have disclosed new treatment opportunities. Indeed, pharmacologic treatment options for thrombocytopenia can be divided into treatments targeted at the thrombopoietin receptor (synthetic thrombopoietins and thrombopoietin-mimetic agents), and use of cytokines with general thrombopoietic potential. Unfortunately, use of synthetic thrombopoietin was hampered by the development of neutralizing antibodies, and thrombopoietin mimetic agents have not yet entered clinical studies. Interleukin-11 proved to be useful in increasing platelet count in patients with chronic liver disease, although its use is limited by side-effects. Erythropoietin has shown promising results in improving thrombocytopenia in cirrhotic patients. In patients with chronic liver disease, safe and well-tolerated treatments aimed at improving thrombocytopenia are still lacking. Larger studies are needed to evaluate and better characterize the thrombopoietic potential of erythropoietin. Human studies with thrombopoietin-mimetic agents are eagerly awaited in order to assess both effectiveness and safety of these drugs.
AuthorsE G Giannini
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 23 Issue 8 Pg. 1055-65 (Apr 15 2006) ISSN: 0269-2813 [Print] England
PMID16611265 (Publication Type: Journal Article, Review)
Chemical References
  • Receptors, Erythropoietin
  • Recombinant Proteins
  • Erythropoietin
  • Thrombopoietin
  • Chronic Disease
  • Controlled Clinical Trials as Topic
  • Erythropoietin (metabolism, therapeutic use)
  • Humans
  • Liver Diseases (blood, drug therapy)
  • Platelet Count
  • Receptors, Erythropoietin (metabolism)
  • Recombinant Proteins
  • Thrombocytopenia (complications, drug therapy)
  • Thrombopoietin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: